Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hirakata-shi
Clinical trial register · Japan

Clinical Trials in Hirakata-shi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2516 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2516
Studies in scope
all four open statuses
1285
Recruiting now
open to new participants
352
Lead sponsors
across recruiting studies
Top sites
Fukuoka 557 Nagoya 513 Sapporo 400 Tokyo 375 Osaka 354
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca21 AbbVie4 Daiichi Sankyo4 Takeda2 Bristol-Myers Squibb2 Amgen2 Alexion Pharmaceuticals, Inc.1 Janssen Pharmaceutica N.V., Belgium1 Chugai Pharmaceutical1 Astellas Pharma Inc1 Taiho Pharmaceutical Co., Ltd.1 Sanofi1 Astellas Pharma Global Development, Inc.1
Site location
Fukuoka557 Nagoya513 Sapporo400 Tokyo375 Osaka354 Chiba328 Kashiwa317 Yokohama272 Kobe239 Kyoto231 Hiroshima224 Sendai207 Chūōku202 Matsuyama172 Bunkyō City171 Kanazawa149 Kumamoto147 Okayama133 Kashiwa-shi132 Niigata120 Fukushima114 Kagoshima107 Kanagawa105 Aichi104 Gifu103 Show all 938
All 938 locations
Target enrolment
to

Trials with a site in Hirakata-shi

42 of 2516 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Bristol-Myers Squibb
Phase 3
850
Nagoya, Toon-Shi, Kurume-Shi, Yokohama, Sendai, Okayama, Hirakata-Shi, Osakasayama-Shi
2026-09-08
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
428
Kashiwa-shi, Hirakata-shi, Chuo-ku, Koto-ku
2026-02-05
Recruiting
AstraZeneca
Phase 3
2,130
Bunkyō City, Chūōku, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku, Kurashiki-shi
2026-02-03
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
20
Bunkyō City, Hirakata-shi, Iruma-Gun, Kyoto, Matsumoto-shi, Miyazaki, Nagoya, Nara
2025-12-19
Recruiting
AbbVie
Phase 1
220
Kashiwa-shi, Hirakata-shi
2025-11-20
Recruiting
Daiichi Sankyo
Phase 3
686
Hidaka-shi, Hirakata-shi, Hirosaki-shi, Kashiwa-shi, Kawasaki-shi, Kitakyushu-shi, Kumamoto, Kurume-shi
2025-10-24
Recruiting
AstraZeneca
Phase 1/2
52
Chūōku, Hirakata-shi, Kashiwa
2025-09-30
Active, closed
Amgen
Phase 3
350
Matsuyama, Fukuoka, Kurume-shi, Sapporo, Akashi-shi, Niigata, Okayama, Hirakata-shi
2025-08-18
Recruiting
Takeda
Phase 3
150
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-08-14
Active, closed
Astellas Pharma Inc
Phase 4
17
Fukushima, Kita-gun, Yokohama, Kyoto, Nagasaki, Ginowan-shi, Hirakata-shi, Suita-shi
2025-07-08
Recruiting
AbbVie
Phase 1
232
Kashiwa-shi, Hirakata-shi, Chuo-Ku
2025-04-14
Recruiting
AstraZeneca
Phase 3
840
Akashi-shi, Bunkyō City, Chūōku, Fukuoka, Hidaka-shi, Hirakata-shi, Hiroshima, Kasama-shi
2025-03-01
Recruiting
Takeda
Phase 3
171
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-02-27
Active, closed
Amgen
Phase 2
252
Kurume-shi, Sapporo, Yokohama, Niigata, Hirakata-shi, Osaka, Sunto-gun, Koto-ku
2025-02-26
Recruiting
AstraZeneca
Phase 3
1,160
Amagasaki-shi, Bunkyō City, Chūōku, Fukuoka, Hirakata-shi, Hiroshima, Kakogawa-shi, Kanazawa
2024-11-18
Recruiting
AstraZeneca
Phase 3
620
Bunkyō City, Chiba, Fukuyama-shi, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kawasaki-shi
2024-08-12
Recruiting
AstraZeneca
Phase 3
1,018
Bunkyō City, Chiba, Chuo-shi, Fukuoka, Hirakata-shi, Kobe, Kōtoku, Kumamoto
2024-08-07
Recruiting
AstraZeneca
Phase 3
788
Chiba, Hidaka-shi, Hirakata-shi, Isehara-shi, Kagoshima, Kashiwa, Kōtoku, Kumamoto
2024-08-01
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Chofu-shi, Chūōku, Hirakata-shi, Kobe, Musashimurayama, Narashino-shi, Shinjuku Ku, Shinjuku-ku
2024-07-22
Recruiting
Daiichi Sankyo
Phase 1/2
123
Himeji-shi, Hirakata-shi, Kashiwa, Kōtoku, Kumamoto, Nagaizumi-cho, Niigata, Okayama
2024-07-22
Recruiting
Daiichi Sankyo
Phase 3
540
Chūōku, Fukuoka, Hirakata-shi, Kashiwa, Kōtoku, Matsuyama, Nakatogari, Okayama
2024-05-21
Recruiting
AstraZeneca
Phase 3
675
Bunkyō City, Fukuoka, Hakodate-shi, Hidaka-shi, Hirakata-shi, Hirosaki-shi, Hiroshima, Kanazawa
2024-04-11
Active, closed
Bristol-Myers Squibb
Phase 2
310
Nagoya, Toride-Shi, Kurashiki-Shi, Hirakata-Shi, Osaka, Bunkyo-Ku, Hachioji-Shi, Setagaya-Ku
2024-03-20
Active, closed
AstraZeneca
Phase 3
1,898
Chiba, Fukuoka, Hirakata-shi, Hirosaki-shi, Kanazawa, Kashihara-shi, Kawagoe-shi, Kisarazu-shi
2023-11-21
Active, closed
AstraZeneca
Phase 3
5,511
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Hirakata-shi, Hiroshima, Iruma-Gun
2023-10-05
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
DrugDS-3939a
Daiichi Sankyo
Phase 1/2
590
Chūōku, Hirakata-shi, Kashiwa, Kōtoku, Kumamoto, Osaka, Ōsaka-sayama, Sapporo
2023-08-18
Recruiting
Chugai Pharmaceutical
Phase 1
209
Nagoya, Kashiwa-shi, Yokohama, Hirakata-shi, Osaka, Sakai-shi, Nagaizumi-chō, Chuo-ku
2023-05-24
Recruiting
AstraZeneca
Phase 3
4,300
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Hirakata-shi, Hiroshima, Isehara-shi
2023-03-31
Active, closed
AstraZeneca
Phase 3
1,035
Chiba, Hirakata-shi, Hirosaki-shi, Kanazawa, Kashihara-shi, Kita-gun, Kobe, Kumamoto
2022-03-25
Recruiting
AbbVie
Phase 1
694
Nagoya, Kashiwa-shi, Kobe, Hirakata-shi, Sunto-gun, Chuo-ku, Wakayama
2021-11-01
Active, closed
AbbVie
Phase 3
132
Nagoya, Tsu, Hirakata-shi, Shinjuku-ku
2021-07-24
Active, closed
AstraZeneca
Phase 3
315
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Kitaadachi-gun, Kōtoku, Kumamoto, Matsuyama
2021-06-30
Active, closed
AstraZeneca
Phase 3
1,371
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Isehara-shi, Kitaadachi-gun, Kōtoku, Kumamoto
2021-01-28
Recruiting
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
NCT04683250RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1/2
244
Kashiwa-shi, Sendai, Okayama, Hirakata-shi, Osaka, Shizuoka, Chuo-ku, Koto-ku
2020-12-16
Active, closed
AstraZeneca
Phase 3
957
Chūōku, Hidaka-shi, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kochi, Kurume-shi
2020-11-17
Active, closed
AstraZeneca
Phase 3
640
Bunkyō City, Chūōku, Hidaka-shi, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku
2020-10-19
Active, closed
AstraZeneca
Phase 3
1,012
Bunkyō City, Chiba, Chūōku, Fukuoka, Hamamatsu, Hirakata-shi, Hirosaki-shi, Isehara-shi
2020-07-13
Active, closed
Sanofi
Observational
955
Nagakute-shi, Obihiro-shi, Sapporo, Hirakata-shi, Koshigaya-shi, Shimotsuga-gun, tabashi City, Amagasaki-shi
2019-06-11
Active, closed
AstraZeneca
Phase 3
895
Bunkyō City, Hirakata-shi, Kanazawa, Kashihara-shi, Kawagoe-shi, Kita-gun, Kyoto, Maebashi
2018-10-31
Active, closed
AstraZeneca
Phase 3
682
Bunkyō City, Fukuoka, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kitakyushu-shi, Kobe
2015-10-21
Active, closed
AstraZeneca
Phase 3
1,118
Fukushima, Himeji-shi, Hirakata-shi, Hirosaki-shi, Iizuka-shi, Iwakuni-shi, Izumi-shi, Kanazawa
2015-07-21
Active, closed
AstraZeneca
Phase 1
344
Chūōku, Habikino-shi, Hirakata-shi, Kashiwa, Nagoya
2014-08-05
Rows per page Showing 1–42 of 42
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-japan/city/hirakata-shi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,516 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 42 of those studies with a site in Hirakata-shi.

How many clinical trials are recruiting in Hirakata-shi?

23 of the 42 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hirakata-shi), 42 studies
PhaseStudiesRecruitingShare
Phase 3261361.9%
Phase 15411.9%
Phase 1/25511.9%
Phase 2307.1%
Phase 4214.8%
Observational102.4%

Most active sponsors

Lead sponsors with the most studies (Hirakata-shi)
Lead sponsorStudiesRecruiting
AstraZeneca219
AbbVie43
Daiichi Sankyo44
Amgen20
Bristol-Myers Squibb21
Takeda22
Alexion Pharmaceuticals, Inc.11
Astellas Pharma Global Development, Inc.11
Astellas Pharma Inc10
Chugai Pharmaceutical11
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.